An unlimited breadth of user-upgradeable application modules expands your research capabilities and evolves with your research
List view / Grid view
Filter the results
Multi-user microplate reader with a large touchscreen and NFC functionality
Unique considerations surrounding the bureaucracy and oversight in the use of human biospecimens in the European Union.
High content data derived for complex immuno-oncology research facilitates a deeper understanding of the tissue microenvironment.
Dr Kaylene Simpson, Peter MacCallum Cancer Center, describes their research using high content imaging to examine RNA in cancer cells.
Michael Johnson and his team at Visikol talk about the work they do as a contract research organization on 3D Cell Cultures and how they utilize High-Content Analysis / Screening to generate insights.
Laura Kilpatrick, Chloe Peach and Carl White from the University of Nottingham talk about cancer research and how they use our microplate readers PHERAstar and CLARIOstar.
This video will show how you can do GPCR binding and signalling studies with the PHERAstar.
In this video, Becky Allsopp from Sygnature Discovery talks about Drug Discovery Research and how she uses the Microplate Reader PHERAstar FSX for their research.
Advanced high-throughput screening in a microplate reader.
Quickly gain new insights into chemical and biomolecular research data. Featuring guided search and analysis workflows and dynamic data visualisations.
6 December 2015 | By ProteinSimple
This video provides an overview of the features from the Simple Western product range by ProteinSimple, including Wes, Sally Sue, Peggy Sue or NanoPro 1000...
Find out about the science behind Affimers - including why Affimers are superior to antibodies and details about our custom Affimer process...
Find out more about the applications of Affimers, including how Affimers can be used in the development of therapeutics...
This video introduces Avacta Life Sciences, part of Avacta Group plc and its flagship product, Affimers - a revolutionary new, engineered alternative to antibodies...